InflaRx N.V. (NASDAQ: IFRX) announced that phase 3 study results for vilobelimab in pyoderma gangrenosum will be presented during a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE